RxDoctor Payments Data

Melinda Headley

Family · Martinsburg, WVNPI 1518637602

Payments from drug & device makers

$2,332in general payments, 2019–2025

Across 110 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$854
  • Lilly USA, LLC$247
  • AstraZeneca$231
  • Pfizer$193
  • GSK$145
  • Corium, LLC$84
  • plus $577 from 15 others

What the payments were for

  • Food & beverage$2,332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,332 in reported general payments places this provider in the 80th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$1,969
Medicare patients
33
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide41$52,756
MounjaroTirzepatide29$41,292
OzempicSemaglutide16$17,604
JardianceEmpagliflozin11$13,973
EliquisApixaban21$13,467
FarxigaDapagliflozin Propanediol16$9,615
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,180
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$1,697
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,634
Rosuvastatin Calcium49$1,424
Duloxetine Hcl23$1,067
Albuterol Sulfate HfaAlbuterol Sulfate36$829
Atorvastatin Calcium96$644
Sertraline Hcl45$524
Famotidine33$483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$247$94,04870 claims
Novo NordiskOzempic$52$17,60416 claims
PfizerEliquis$193$13,46721 claims
AstraZenecaFarxiga$231$9,61516 claims
GSKTrelegy Ellipta$145$8,18013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,507 family providers in West Virginia.

Other family in Martinsburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →